南京诺唯赞生物科技股份有限公司关于持股5%以上股东权益变动触及1%刻度的提示性公告

Core Viewpoint - The announcement details a change in equity ownership by a major shareholder of Nanjing Novogene Biotechnology Co., Ltd., indicating a reduction in shareholding that touches the 1% threshold, which is significant for regulatory reporting [4][5]. Group 1: Shareholder Information - The shareholder involved is Guoshou Chengda (Shanghai) Health Industry Equity Investment Center (Limited Partnership), which has confirmed the accuracy and completeness of the information provided [1][2]. - There are no associated parties with the information disclosure obligor [3]. Group 2: Equity Change Details - From November 12, 2025, to December 19, 2025, Guoshou Chengda reduced its shareholding by 3,185,792 shares, representing 0.80% of the total share capital of the company [4]. - Following this reduction, Guoshou Chengda's total shareholding decreased from 30,957,960 shares to 27,772,168 shares, lowering its ownership percentage from 7.78% to 6.98% [4]. Group 3: Additional Notes - This equity change is part of a previously disclosed share reduction plan and does not trigger a mandatory tender offer [5]. - The change in equity will not affect the company's controlling shareholder or actual controller, nor will it significantly impact the company's governance structure or ongoing operations [5]. - The company will continue to comply with relevant regulations and fulfill its information disclosure obligations [6].